T0	Participants 115 129	GERD patients.
T1	Participants 215 263	gastro-esophageal reflux disease (GERD) patients
T2	Participants 483 497	GERD patients.
T3	Participants 506 643	Forty-seven GERD patients randomized to endoscopic fundoplication (n = 32) or PPI therapy (n = 15), and 29 healthy controls were included
T4	Participants 872 898	impedance in GERD patients
T5	Participants 909 933	than in healthy controls
T6	Participants 1560 1581	baseline impedance in